FDA Drug Safety Committee To Discuss Use Of Post-Marketing Studies May 19
This article was originally published in The Pink Sheet Daily
Executive Summary
The Drug Safety & Risk Management Advisory Committee will consider the utility of various types of post-market studies in detecting and quantifying risk.
You may also be interested in...
Drug Safety Surveillance Based On Medicare Data Should Top List Of FDA Priorities
Implementation of the Medicare drug benefit provides an opportunity for an active surveillance system to collect drug safety data, Drug Safety & Risk Management Advisory Committee members say. Active surveillance can act as a safety net for FDA's adverse events signaling system.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications